PF643 CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULT... von Voorhees, P.M., Fonseca, R., Cote, S., Lam, A., Ukropec, J., Maiese, E., Potluri, R., Nair, S., Mehra, M.

Volltext

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogene... von S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia

Volltext

PS1372 B‐CELL MATURATION ANTIGEN ANTIBODY‐DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES... von Popat, R., Lendvai, N., Trudel, S., Voorhees, P.M., Reeves, B., Libby, E.N., Richardson, P.G., Jr, L.D. Anderson, Sutherland, H.J., Yong, K., Hoos, A., Gorczyca, M.M., He, Z., Jewell, R.C., Dettman, E.J., Rigat, F., Gupta, I., Bragulat, V., Opalinska, J.B., Cohen, A.D.

Volltext